Monoclonal antibody (mAb) therapy against tumor antigens expressed on the tumor surface is associated with clinical benefit. However,many tumor antigens are intracellularmolecules that generallywould not be considered suitable targets formAb therapy. In this study, we provide evidence challenging this view through an investigation of the efficacy of mAb directed against NY-ESO-1, a widely expre...

When rainbow trout Oncorhynchus mykiss (mean weight, 4.3 g ) were injected with 100 p1 of anti-infectious hematopoietic necrosis virus (IHNV) rainbow trout immune serum (IHNV neutralizing titer 640) immediately following waterborne exposure to 10' plaque-forming units ml-' of IHNV, relative protection was 91 'X compared to fish injected with normal serum (titer < 20). Fish injected with immune ...

Recent publications from this laboratory (1, 2) have shown that it is possible to cause the regression of established immunogenic murine tumors by the passive transfer of tumor-sensitized T cells from immunized donors, provided the tumor-bearing recipients have been made T cell-deficient by thymectomy and irradiation. The need for T cell-deficient tumor-bearing recipients to demonstrate success...

Recent publications from this laboratory (1, 2) have shown that it is possible to cause the regression of established immunogenic murine tumors by the passive transfer of tumor-sensitized T cells from immunized donors, provided the tumor-bearing recipients have been made T cell-deficient by thymectomy and irradiation. The need for T cell-deficient tumor-bearing recipients to demonstrate success...

9. Ross LA, Kim KS, Mason WH Jr, Gomperts E. Successful treatment of disseminated measles in a patient with acquired immunodefi ciency syndrome: consideration of antiviral and passive immunotherapy. Am J Med. 1990;88:313–4. http://dx.doi.org/10.1016/0002-9343(90) 90162-7 10. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and thera...

Cancer immunotherapy is the use of the immune system to reject cancers. The main premise is to harness the patient's immune system to attack the malignant tumor cells. This area of research has made tremendous progresses, and the United States Food and Drug Administration recently approved a vaccine for prostate cancers as the first approval for vaccines against non-viral cancers (Kantoff et al...

BACKGROUND In the current treatment paradigms for leukemias, hematopoietic stem cell transplant (HSCT) is considered the best option with a curative potential although more often than not it simply delays disease progression. Advances are needed, both in current therapies and in the development of new strategies. Partly from studying the nuances of the curative potential of stem cell transplant...

Immunotherapy might provide an effective treatment for Alzheimer disease (AD). A unique feature of AD immunotherapies is that an immune response against a self antigen needs to be elicited without causing adverse autoimmune reactions. Current research is focussed on two possible targets in this regard: One is the inhibition of accumulation and deposition of Amyloid beta 1-42 (Aβ42), which is on...